Evidence map›Paper›PMID 35513850›Full record

ArticleGenome medicine2022

A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets.

Xinxiu Li, Eun Jung Lee, Sandra Lilja, Joseph Loscalzo, Samuel Schäfer, Martin Smelik, Maria Regina Strobl, Oleg Sysoev, Hui Wang, Huan Zhang and 4 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Preparing Allergists to Practice in 2050 Using Artificial Intelligence.The journal of allergy and clinical immunology. In practice · 2025
    Review
  5. Review
  6. Utilization of precision medicine digital twins for drug discovery in Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  7. Article
  8. Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  9. Review
  10. Article
  11. Multi-Omics and Single-Cell Omics: New Tools in Drug Target Discovery.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Article
  12. Article
  13. Article
  14. Digital Twins of Biological Systems: A Narrative Review.IEEE open journal of engineering in medicine and biology · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 5 countries.

Xinxiu Li *Centre for Personalized Medicine, Linköping University, Linköping, Sweden.
Eun Jung Lee *Centre for Personalized Medicine, Linköping University, Linköping, Sweden.
Sandra Lilja *Centre for Personalized Medicine, Linköping University, Linköping, Sweden.
Joseph LoscalzoDepartment of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Samuel SchäferCentre for Personalized Medicine, Linköping University, Linköping, Sweden.
Martin SmelikCentre for Personalized Medicine, Linköping University, Linköping, Sweden.
Maria Regina StroblDepartment of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Oleg SysoevDivision of Statistics and Machine Learning, Department of Computer and Information Science, Linkoping University, Linköping, Sweden.
Hui WangJiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Huan ZhangCentre for Personalized Medicine, Linköping University, Linköping, Sweden.
Yelin ZhaoCentre for Personalized Medicine, Linköping University, Linköping, Sweden.
Danuta R Gawel *Centre for Personalized Medicine, Linköping University, Linköping, Sweden.
Barbara Bohle *Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
Mikael Benson *Centre for Personalized Medicine, Linköping University, Linköping, Sweden. mikael.benson@liu.se.ORCID 0000-0002-7753-9181
Linköping University · SEMedical University of Vienna · ATBrigham and Women's Hospital · USXuzhou Medical College · CN

Funding

Boston Biomedical Innovation CenterU54HL119145 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLAN, DAVID E., LOSCALZO, JOSEPH · 2013 to 2021
$18.8M
Center for Integrated Approaches to Undiagnosed DiseasesU01HG007690 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSCALZO, JOSEPH · 2014 to 2022
$10.4M
L-2-Hydroxyglutarate and Metabolic Remodeling in HypoxiaR01HL155107 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Joseph Loscalzo · 2021 to 2026
$4.1M
The Phathophenotype Landscape of Complex DiseaseU01HL108630 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSCALZO, JOSEPH · 2011 to 2014
$2.7M
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertensionR01HL155096 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI MARON, BRADLEY · 2021 to 2024
$1.6M
Austrian Science Fund FWF I 4437Austrian Science Fund FWF P 32953NHGRI NIH HHS U01 HG007690NHLBI NIH HHS R01 HL155096NHLBI NIH HHS R01 HL155107NHLBI NIH HHS U01 HL108630NHLBI NIH HHS U54 HL119145
6 · The paper itself

Abstract

backgroundMedical digital twins are computational disease models for drug discovery and treatment. Unresolved problems include how to organize and prioritize between disease-associated changes in digital twins, on cellulome- and genome-wide scales. We present a dynamic framework that can be used to model such changes and thereby prioritize upstream regulators (URs) for biomarker- and drug discovery.

methodsWe started with seasonal allergic rhinitis (SAR) as a disease model, by analyses of in vitro allergen-stimulated peripheral blood mononuclear cells (PBMC) from SAR patients. Time-series a single-cell RNA-sequencing (scRNA-seq) data of these cells were used to construct multicellular network models (MNMs) at each time point of molecular interactions between cell types. We hypothesized that predicted molecular interactions between cell types in the MNMs could be traced to find an UR gene, at an early time point. We performed bioinformatic and functional studies of the MNMs to develop a scalable framework to prioritize UR genes. This framework was tested on a single-cell and bulk-profiling data from SAR and other inflammatory diseases.

resultsOur scRNA-seq-based time-series MNMs of SAR showed thousands of differentially expressed genes (DEGs) across multiple cell types, which varied between time points. Instead of a single-UR gene in each MNM, we found multiple URs dispersed across the cell types. Thus, at each time point, the MNMs formed multi-directional networks. The absence of linear hierarchies and time-dependent variations in MNMs complicated the prioritization of URs. For example, the expression and functions of Th2 cytokines, which are approved drug targets in allergies, varied across cell types, and time points. Our analyses of bulk- and single-cell data from other inflammatory diseases also revealed multi-directional networks that showed stage-dependent variations. We therefore developed a quantitative approach to prioritize URs: we ranked the URs based on their predicted effects on downstream target cells. Experimental and bioinformatic analyses supported that this kind of ranking is a tractable approach for prioritizing URs.

conclusionsWe present a scalable framework for modeling dynamic changes in digital twins, on cellulome- and genome-wide scales, to prioritize UR genes for biomarker and drug discovery.

Indexed as

Gene Expression ProfilingSingle-Cell AnalysisBiomarkersComputational BiologyHumansLeukocytes, MononuclearBiomarkersInflammatory diseasesMulticellular network modelsScRNA-seqUpstream regulators

Identifiers

PMID35513850
PMCPMC9074288
OpenAlexW4228998153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.